Abstract:Background: Cancer-associated fibroblasts (CAFs) are one of the major components of prostate stromal cells, which play a crucial part in tumor development and treatment resistance. This study aimed to establish a model of CAFs-related microRNAs (miRNAs) to assess prognostic differences, tumor microenvironments, and screening of anticancer drugs by integrating data from single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (buRNA-seq). Methods: scRNA-seq and buRNA-seq data of primary prostate cancer (PCa) were downloaded from Gene Expression Omnibus and The Cancer Genome Atlas databases. Statistical methods including Least absolute shrinkage and selection operator (Lasso), Lasso penalized, Random Forest, Random Forest Combination, and Support Vector Machine (SVM) were performed to select hub miRNAs. Pathway analyses and assessment of infiltrating immune cells were conducted using Gene Set Enrichment Analysis and the CIBERSORT algorithm. The expression of CAFs-related miRNAs in fibroblast cell lines were validated through quantitative real-time PCR. Cell Counting Kit 8 (CCK8), wound-healing, clone formation, and cell migration assays were used to explore cell proliferation, growth, and migration in vitro. A mouse xenograft model was established to investigate the effect of CAFs on tumor growth in vivo. Results: Through single-cell transcriptomics analysis in 34 PCa patients, 89 CAFs-related mRNAs were identified. A prognostic model based on 9 CAFs-related miRNAs (hsa-miR-1258, hsa-miR-133b, hsa-miR-222-3p, hsa-miR-145-3p, hsa-miR-493-5p, hsa-miR-96-5p, hsa-miR-15b-5p, hsa-miR-106b-5p, and hsa-miR-191-5p) was established to predict biochemical recurrence (BCR). We have determined through two prediction methods that NVP-TAE684 may be the optimal targeted therapy drug for treating CAFs. Downregulation of hsa-miR-106b-5p in CAFs significantly suppressed cell proliferation, migration, and colony formation in vitro. In vivo studies using a xenograft model further confirmed that hsa-miR-106b-5p downregulation significantly reduced tumor growth. Conclusion: Our findings conducted an integrated bioinformatic analysis to develop a CAFs-related miRNAs model that provides prognostic insights into individualized and precise treatment for prostate adenocarcinoma patients. Downregulation of miR-106b-5p in CAFs significantly suppressed tumor growth, suggesting a potential therapeutic target for cancer treatment.

Data from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Supplementary Figure 6 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Nonconserved Mir‐608 Suppresses Prostate Cancer Progression Through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 Pathways by Targeting the 3′‐utrs of RAC2/BCL2L1 and the Coding Region of PAK4

Supplementary Materials and Methods, Figure Legends, Tables 1 - 9 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Supplementary Figure 2 from Identification of Mir-133B and RB1CC1 As Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Mir-21 As An Independent Biochemical Recurrence Predictor And Potential Therapeutic Target For Prostate Cancer

Tissue-Based MicroRNAs As Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

An Integrated Bioinformatics Analysis to Investigate the Targets of Mir-133A-1 in Breast Cancer

Micro-ribonucleic Acid 29b Inhibits Cell Proliferation and Invasion and Enhances Cell Apoptosis and Chemotherapy Effects of Cisplatin Via Targeting of DNMT3b and AKT3 in Prostate Cancer

Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer

Expression of Microrna-99A-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases

miR-31-5p Regulates 14-3-3 ɛ to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway.

MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data

Identification of the Key MicroRNAs and the miRNA-mRNA Regulatory Pathways in Prostate Cancer by Bioinformatics Methods

Identification of miRNA signature in cancer-associated fibroblast to predict recurrent prostate cancer

Mir-625-3p Promotes Migration and Invasion and Reduces Apoptosis of Clear Cell Renal Cell Carcinoma.

Mir-137-3p Modulates the Progression of Prostate Cancer by Regulating the JNK3/EZH2 Axis.

Identification of Mir-130B As an Oncogene in Renal Cell Carcinoma

Tumor Suppressor Mir-33B-5p Regulates Cellular Function and Acts a Prognostic Biomarker in RCC.

Mir-663 Induces Castration-Resistant Prostate Cancer Transformation and Predicts Clinical Recurrence

Mir‑27b‑3p and Mir‑607 Cooperatively Regulate BLM Gene Expression by Directly Targeting the 3'‑UTR in PC3 Cells.